Adipotide
- Category
- Weight Management & Metabolic
- Administration routes
- Injectable
- Regulatory status
- Not FDA-approved
What it is
A synthetic peptide designed to destroy blood vessels feeding white fat, binding prohibitin to trigger endothelial cell death, marketed for rapid fat loss. The case rests entirely on animal studies; there is no human trial evidence. The headline concern is dose-dependent kidney toxicity, documented in primates, with no long-term human safety data. Not an approved drug; human use relies on unregulated products sold online.
Read Full recordStudied uses & evidence
Studied uses(8)
Rapid weight loss in animal models (7.4-14.7% body weight reduction in 28 days in primates)
LowTreated primates lost 7.4 to 14.7% body weight over 28 days; no human data exist.
Selective targeting of white adipose tissue vasculature without affecting lean body mass
LowMechanism confirmed in mice and primates; lean mass sparing is a secondary, less rigorous endpoint.
Marked improvement in insulin resistance (insulin AUC decreased 36% in obese primates)
LowIn obese monkeys, adipotide lowered insulin AUC by 36% after four weeks of treatment.
Evidence limits
Strong preclinical evidence in mice and nonhuman primates. A single Phase 1 human trial (NCT01262664) was initiated in 2012 at MD Anderson Cancer Center in obese patients with castrate-resistant prostate cancer. The trial evaluated five dose levels across a 28-day subcutaneous injection cycle. No human results have been published. The trial was terminated at the principal investigator's request; a toxicity-related reason was not established.
Benefits = confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)
Cautions & risk summary
General cautions
Pregnancy or breastfeeding
AbsoluteNo human reproductive safety data exists for this peptide. Effects on fetal development are unknown.
Children under 18
AbsoluteNo pediatric safety data. Not recommended for use in minors.
Known hypersensitivity
AbsoluteDiscontinue immediately if allergic reaction occurs (rash, swelling, difficulty breathing).
Risk summary(13)
Risks = level of concern: High · Moderate · Low · Theoretical
Dose-dependent renal tubular toxicity observed in primates
HighElevated serum creatinine indicating kidney stress (reversible upon cessation in animal studies)
ModerateMild to marked glucosuria (glucose in urine)
ModerateMild to moderate proteinuria (protein in urine)
ModerateDecreased serum phosphorus and potassium levels
ModerateIncreased urinary renal epithelial cells indicating tubular damage
ModerateHistological findings of minimal-to-mild tubular degeneration and single-cell necrosis in kidneys
ModerateMild dehydration at higher doses
ModerateInjection site reactions
LowFatigue reported in some preclinical observations
TheoreticalNo long-term human safety data available — all safety data from animal studies only
HighPotential off-target vascular effects in non-adipose tissues not fully characterized
ModerateNot approved for human use — any human use is entirely experimental and unregulated
High
Further reading
- Overview in Full record
- Safety & interactions in Full record
- Research & benefits in Full record
- Regulation & availability in Full record
- Sources in Full record
- Frequently asked questions in Full record
This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer
Compiled from published research indexed through March 2026.